An 18-months Open Label Phase I Follow-up Study on Patients With Alzheimer's Disease Who Have Completed the AADvac1 Phase I Study 'AXON CO 18700'

Trial Profile

An 18-months Open Label Phase I Follow-up Study on Patients With Alzheimer's Disease Who Have Completed the AADvac1 Phase I Study 'AXON CO 18700'

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs AADvac 1 (Primary) ; Aluminium hydroxide
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms FUNDAMANT
  • Sponsors Axon Neuroscience
  • Most Recent Events

    • 15 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 13 Dec 2016 According to AXON Neuroscience media release, results were presented at the 9th International Conference on Clinical Trials in Alzheimers Disease (CTAD) 2016.
    • 15 Jul 2016 Planned End Date changed from 1 Sep 2017 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top